Deutsche Bank AG Decreases Position in 4D Molecular Therapeutics, Inc. $FDMT

Deutsche Bank AG cut its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 2.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 236,157 shares of the company’s stock after selling 5,696 shares during the period. Deutsche Bank AG owned 0.51% of 4D Molecular Therapeutics worth $763,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Y Intercept Hong Kong Ltd bought a new stake in shares of 4D Molecular Therapeutics during the 1st quarter worth approximately $41,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of 4D Molecular Therapeutics during the 4th quarter worth approximately $50,000. Velan Capital Investment Management LP bought a new stake in shares of 4D Molecular Therapeutics during the 4th quarter worth approximately $56,000. Virtus ETF Advisers LLC lifted its stake in shares of 4D Molecular Therapeutics by 173.9% during the 4th quarter. Virtus ETF Advisers LLC now owns 10,333 shares of the company’s stock worth $58,000 after acquiring an additional 6,560 shares during the last quarter. Finally, Proficio Capital Partners LLC lifted its stake in shares of 4D Molecular Therapeutics by 26.0% during the 1st quarter. Proficio Capital Partners LLC now owns 25,195 shares of the company’s stock worth $75,000 after acquiring an additional 5,195 shares during the last quarter. 99.27% of the stock is owned by institutional investors.

4D Molecular Therapeutics Trading Down 4.9%

Shares of NASDAQ:FDMT opened at $6.74 on Tuesday. 4D Molecular Therapeutics, Inc. has a 12-month low of $2.23 and a 12-month high of $17.41. The business’s fifty day simple moving average is $4.97 and its 200-day simple moving average is $4.16. The company has a market capitalization of $314.76 million, a PE ratio of -1.91 and a beta of 2.83.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.10). 4D Molecular Therapeutics had a negative net margin of 594,375.81% and a negative return on equity of 40.15%. The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.52 million. Research analysts predict that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on FDMT. Chardan Capital reissued a “buy” rating and set a $25.00 price target on shares of 4D Molecular Therapeutics in a research note on Tuesday, August 12th. Barclays decreased their price target on 4D Molecular Therapeutics from $45.00 to $38.00 and set an “overweight” rating for the company in a research note on Friday, May 9th. Roth Capital reduced their price objective on 4D Molecular Therapeutics from $44.00 to $38.00 and set a “buy” rating on the stock in a report on Tuesday, August 12th. The Goldman Sachs Group reduced their price objective on 4D Molecular Therapeutics from $51.00 to $44.00 and set a “buy” rating on the stock in a report on Friday, May 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Thursday, August 14th. Eight investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $30.40.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.